Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) Shares Outstanding (Weighted Average) (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $766598.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 39.34% to $766598.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $766598.0, a 39.34% increase, with the full-year FY2025 number at $766598.0, up 39.34% from a year prior.
  • Shares Outstanding (Weighted Average) was $766598.0 for Q4 2025 at Spruce Biosciences, up from $589520.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $43.9 million in Q1 2025 to a low of $548789.0 in Q2 2024.
  • A 4-year average of $20.7 million and a median of $23.5 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 72.59% in 2023, then tumbled 98.65% in 2024.
  • Spruce Biosciences' Shares Outstanding (Weighted Average) stood at $23.5 million in 2022, then surged by 63.68% to $38.5 million in 2023, then crashed by 98.57% to $550146.0 in 2024, then soared by 39.34% to $766598.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Shares Outstanding (Weighted Average) are $766598.0 (Q4 2025), $589520.0 (Q3 2025), and $588653.0 (Q2 2025).